ALS Biopharma Press Release

Doylestown, PA. March 11, 2011:

ALS Biopharma, LLC is pleased to report that MDA Venture Philanthropy of Tuscon, AZ ( has awarded the company a grant of $250,000 to advance heat shock protein Hsp70-based biological therapy into the mSOD1 mouse animal model prior to selection of a biologic candidate for further IND-enabling studies and clinical evaluation to treat ALS and related neuropathies. "We greatly appreciate this support from the Muscular Dystrophy Association," said Dr. Allen Reitz, CEO of ALS Biopharma. "We are moving as quickly as possible to realize the research objectives we have agreed upon together."

Back to Press Releases